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Background: Attention-deficit hyperactivity disorder (ADHD) is a mental disorder beginning in childhood, and
about half of patients have symptoms lasting into adulthood. Adult ADHD causes various impairments of
emotional, self-esteem, and executive function and life quality aspects. Furthermore, adverse outcomes include
academic and occupational failures, traffic accidents and substance abuse, which would be a family and social
burden. A combination of medication and psychotherapy is recommended as the treatment for adult ADHD, and
cognitive behavioral therapy (CBT) has been validated mostly with evidence-based researches. However, there has
been a lack of randomized controlled trials of CBT for patients in China. Moreover, booster sessions of CBT for other
disorders have proven effective in reducing recurrence and improving long-term outcomes, which has not been
investigated for adult ADHD. This study will testify to the effect of CBT and explore the efficacy of subsequent
booster sessions on adult ADHD.
Methods/Design: It is a three-armed randomized controlled trial to evaluate the efficacy of 12 weeks of CBT based
on the published and validated manual and its booster sessions. The 12 weeks of CBT will be conducted weekly
and will end at the 12th week, and then the booster sessions will be conducted monthly and end at the 24th
week. There are three randomized groups, including a CBT with booster sessions group, a CBT group and a waiting
group. Participants are outpatients of the Peking University Sixth Hospital who are diagnosed as having adult
ADHD. The Primary efficacy endpoints are the scores of ADHD core symptoms at 12 and 24 weeks. Secondary
endpoints include emotion, executive function, self-esteem, life quality and functional magnetic resonance
imaging (fMRI) data at different time points, and the change within every group will also be analyzed.
Discussion: This is the first study to explore the efficacy of booster sessions of CBT in adult ADHD as far as we
know. The results might increase proof of efficacy of CBT for adult ADHD in China, and the results showing efficacy
of the booster sessions would also benefit our clinical practice.
Trial registration: Current Controlled Trials: NCT02062411, date of registration: 12 February 2014.
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Attention-deficit hyperactivity disorder (ADHD) begins in
childhood [1], and 50% of patients have symptoms lasting
into adulthood [2]. The prevalence of adult ADHD is
about 5% [3]. There are different adverse outcomes along
with adult ADHD including comorbidities as depression
and anxiety; cognitive function impairment; social dys-
functions such as procrastination, dropping out of school,
and being laid off; increasing rates of traffic accidents; sub-
stance abuse; and decreases in quality of life [4-8]. This
disease could cause a great burden of society, and the hu-
man capital value was reported as $4,336 per worker for a
single year in the United States [9]. The clinical treatment
guideline recommends a combination of medication and
psychotherapy as the first line therapy method for adult
ADHD [10,11], and the cognitive behavioral therapy
(CBT) has been validated mostly with evidence-based re-
searches [12-15].
The efficacy of CBT in adult ADHD has been proven
in several randomized studies on the aspects of core
symptoms, emotion, self-esteem and time-management
strategies [12-15]. Studies also found the efficacy of
CBT was superior to relaxation with educational sup-
port [13] and computerized cognitive training [16].
Compared with medication, CBT could also improve pa-
tients’ADHD symptoms without previous medical treat-
ment, which might suggest that the mechanism of CBT
did not fully rely on medication [14]. However, the pre-
vious studies mainly focused on some selected aspects
of CBT’s efficacy, and the multidimensional impair-
ments that proved to be prominent for adult ADHD pa-
tients [4-8] had not been tested in the same group of
subjects, which left the measurement of CBT’s efficacy
remaining to be explored [17]. Our group’s self-control
study also found preliminary evidence of the efficacy of
12 weeks of CBT in a Chinese population [18,19], which
needs to be further validated in a randomized controlled
study.
A review of CBT studies for adult ADHD emphasizes
that evidence of long-term outcomes is limited [17].
Through the follow-up of treated patients from our
group study, which only used 12 weeks of CBT as de-
scribed in the manual [18], we found that patients for-
got the skills they learned in CBT and had difficulties in
applying them into practice in real life. The booster ses-
sions were previously used in behavior therapy to
achieve sustaining results, and a review of 30 clinical tri-
als concluded that the booster sessions were useful in
maintaining behavioral change [20]. With regard to
CBT, according to studies covering depression [21,22],
bipolar disorder [23], panic disorder [24] and binge eat-
ing disorder [25], providing the booster sessions or the
maintaining treatment after the completion of CBT
would reduce the recurrence rate and benefit the long-term effect. Furthermore, the latest meta-analyses found
that CBT with booster sessions was more effective and
had more sustainable outcomes for children with mood or
anxiety disorders [26]. To date, three CBT studies for adult
ADHD have included periods as booster sessions [13,14,27];
however, the specific effects of this process have not been in-
vestigated. In Safren’s study, there is an optional session that
contains review and summary of the previous lessons [13].
There were two booster sessions in Weiss’s research at 15
and 20 weeks [14], and 10 booster sessions monthly in
Philipsen’s study protocol after 12 weeks of group therapy
[27]. None of these above studies considered these periods
as separate from the treatment or explored their role in the
integrated treatment.
The integration of known CBT interventions for other
disorders in adult ADHD remain to be explored [17].
So, we wonder whether the booster sessions could help
CBT in fulfilling the skill-teaching and practicing mis-
sions, thereby prolonging the efficacy for adults with
ADHD. This study is conducted to test whether CBT is
effective in the treatment of attention-deficit and emo-
tional, executive and social impairments due to ADHD
in a randomized controlled design and to explore the
role booster sessions played in the CBT process.Objectives/hypotheses
The primary research questions are as follow: (1) Is CBT
effective in the treatment of adult ADHD and related
problems? and (2) Is the treatment effect of CBT with
booster sessions superior to that of CBT only?
There are still other questions: (1) Would booster sessions
improve the patients’ satisfaction at evaluation? The subject-
ive evaluation would reflect the acceptability of the treat-
ment, especially in psychotherapy, and these measurements
might reflect factors that work other than outcomes of
scales or behavioral tests [15,28]. (2) Are there some signifi-
cant factors that can predict or influence the outcome, in-
cluding symptom severity, comorbidity, social and economic
status, and neuropsychological or neuroimaging biological
markers? The role of baseline situations in CBT for adult
ADHD remains unclear, and the possible biological
markers might benefit finding the “working factors”
in CBT [17,29,30]. (3) Would the effects of CBT cause
some neuroimaging changes? The neuroimaging methods
would provide the biological evidence of treatment and
benefit exploring the mechanism of psychotherapy [29].
(4) Finally, considering the limited evidence of long-term
effects [17,30], how long the outcomes last would also be
evaluated.
The hypothesis of this study is that CBT reduces
ADHD symptoms compared to nonintervention, and
CBT with booster sessions reduces more ADHD symp-
toms compared to CBT only.
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Study design
We use a three-armed study design in order to evaluate the
effect of CBT on ADHD adults compared with no interven-
tion condition and the effect of 12 weeks CBT with booster
sessions versus 12 weeks CBT only. There are three ran-
domized groups, including a CBT with booster sessions
group (group 1), a CBTgroup (group 2) and a waiting group
(group 3).
The primary and secondary outcomes will be evaluated
at baseline (T1), after 12 weeks of treatment (T2) and after
three booster sessions, which is at 24 weeks (T3). Moreover,
two ADHD symptom evaluation scales and two emotion
evaluation scales will be rated weekly during the 12 weeks
of treatment in order to monitor the changes. Patients of
the CBT with booster sessions group (group 1) will be
followed up at 36 weeks and 48 weeks. Furthermore, the
follow-up will be conducted at 24 weeks, 36 weeks and
48 weeks for patients of the CBT group (group 2), and will
be at 12 weeks for the waiting group (group 3) patients
(Figure 1). Considering the interest of the waiting group pa-
tients, on request, we will provide them with 12 weeks of
CBT at no charge after the study.Figure 1 Trial flow. W, week; CBT, cognitive behavioral therapy.This study is conducted in the Peking University Sixth
Hospital and funded by Beijing Municipal Science and
Technology Commission. The research is based on good
clinical practice standards (GCP) and the CONSORT
statement [31,32], which received ethics approval from
Ethics Committee of the Sixth Hospital of Peking Univer-
sity ((2013) Ethics review number (42)). It has been regis-
tered in ClinicalTrials.gov (NCT02062411).
Intervention
In this study, 12 weeks of CBT is being conducted accord-
ing to a published and validated [12,13] manual (Mastering
Your Adult ADHD: A Cognitive-Behavioral Therapy Ap-
proach, Safren SA, Perlman CA, Sprich S, Otto MW, 2005)
[33]. The original manual consisted of three core modules
and two optional modules, and we put all five modules into
practice. The first part (five sessions) consists of psychoedu-
cation; supportive relationships; and organizational skills
such as using a calendar system, breaking tasks into small
steps and evaluating the benefits and shortcomings of
choices. The second part (two sessions) is mainly about
coping with distractibility, including the skill to record dis-
tractive thoughts and management of the surroundings.
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which helps patients identify the maladjusted automatic
thoughts and change them into adaptive ones. The last part
(two sessions) includes dealing with procrastination with all
the learned skills and summary. All the 12 sessions are con-
ducted once a week at weekends. The English manual was
translated into Chinese by our group’s senior psychiatrists
who received psychotherapy training, and the Chinese edi-
tion was applied to two different groups of patients in self-
control studies, which was effective for reducing ADHD
symptoms and improving everyday life executive function,
self-esteem and life quality [18,19].
The booster sessions are designed according to the defin-
ition of booster sessions in studies of ADHD [13,14,27] and
other diseases [21-25], the main goal of which is consolidat-
ing the skills learned and developing strategies dealing with
recurrence or relapse. Thus, the booster sessions in the
present study contain the induction of the first three parts
above and practicing activities based on the patients’ ques-
tions in the real world. The first booster session includes a
summary of the first organizational part of the 12-week
manual. It also includes other important time-management
skills such as goal setting, reward system and authorizing
others [34], and a discussion of the practice questions
through role-play. The second booster session consists of
the summary of the distractibility part, the discussion of the
relationship between distractibility and procrastination, and
making a self-coping list. The last booster session includes
a summary of the cognition part, the discussion of auto-
matic thoughts of real situation by role-play, and the rela-
tionship between automatic thoughts and procrastination.
These three booster sessions are conducted monthly after
the complement of 12 weeks of CBT.
Participants
The subjects mainly are outpatients of the Peking Uni-
versity Sixth Hospital. Patients who read the recruitment
on the internet, come to the outpatient service and meet
the inclusion criteria will also be included. All subjects
will be fully informed about the research before being
asked to sign the informed consent form.
Patients with adult ADHD are recruited. With regard to
the former treatment, we include people who have been
stable on medications for adult ADHD for at least 2 months
(drug dose was adjusted within 10% in last two months
[13]). The key inclusion criteria include the following:
1. Outpatients from Peking University Sixth Hospital,
who have received a diagnosis of adult ADHD
through Conners’ Adult ADHD Diagnostic Interview
[35] based on Diagnostic and statistical manual of
mental disorders, Fourth Edition (DSM-IV).
2. Patients who are either medication naive or have
been stable on medications (for the treatment ofADHD, drug dosage adjustment in last two months
was below 10% [12]) for adult ADHD for at least
2 months.
Furthermore, patients with comorbidity that may influ-
ence the study outcomes or need extra treatment are ex-
cluded. Patients who are at risk for suicide, in unstable
physical condition, or have received psychological treat-
ment will be excluded. To make some cognition function
assessments possible, people who are older than 45 years
old or have intelligence quotient (IQ) less than 90 will be
excluded. The key exclusion criteria include the following:
1. Severe major depression, clinically significant panic
disorder, bipolar disorder, organic mental disorders,
psychotic disorders, or pervasive developmental
disorders
2. Age older than 45, which might influence outcomes
of cognitive tests [36] or IQ less than 90 [12]
3. Suicide risk
4. Unstable physical condition, which needs medical
treatment prior to ADHD such as active hepatitis
and angina pectoris
5. Prior or present participation in other psychological
therapies.
Outcome measures
The primary efficacy endpoint is an ADHD Rating Scale
(ADHD-RS) [37] score at 12 and 24 weeks. We will measure
the different scores between the waiting group (group 3)
and the CBTgroup (group 2) at 12 weeks to prove the effect
of 12 weeks CBT on adult ADHD, and between the CBT
with booster sessions (group 1) and the CBT group (group
2) at 24 weeks to explore the effect of booster sessions.
The main secondary endpoints will include the following:
 ADHD symptoms (Conners Adult ADHD Rating
Scale Self-report Screening Version [38]) at 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 36, 48 weeks
 Emotional symptomatology (Self-rating Anxiety
Scale [39], Self-rating Depression Scale [40]) at 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 36, 48 weeks
 Executive function (Behavior Rating Inventory of
Executive Function-Adult Version (BRIEF-A) [41],
Cambridge Neuropsychological Testing Automated
Battery (CANTAB) [42] at 12, 24, 48 weeks
 Impulsiveness (Barratt impulsiveness scale [43])
at 12, 24, 48 weeks
 Self-esteem (self-esteem scale [44]) at 12, 24,
48 weeks
 Life quality (World Health Organization Quality of
Life-Brief Version [45]) at 12, 24, 48 weeks
 Neuroimaging (Brain Oxygenation Level Dependent
Signal) at 12 weeks.
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in Table 1. The reasons we used these instruments to
measure the efficacy are explained below. Since the
ADHD symptoms are the main target of treatment and
this manual was specifically designed for ADHD, the
measurement of core ADHD symptoms is significant for
confirming the effect of CBT. And the level of impulsive-
ness may manifest the core impairment of ADHD [46]. It
was reported that emotional disorders were common for
adult ADHD as comorbidities (the lifetime comorbid rates
were 19.4% for generalized anxiety disorder and 28% for
major depression [47]) and 32% of ADHD adults had
emotional dysregulation [48], which makes it important to
monitor the change of emotion during the intervention.
Furthermore, the latest meta-analysis proved that CBT
was effective for depression and anxiety [49], so the emo-
tional results would be positive. The executive function of
ADHD adults was reported to be impaired [50], and the
BRIEF-A and the CANTAB could test both the ecological
and practical aspect [51]. Moreover, the levels of self-
esteem and life quality of ADHD adults were also proven
to be lower than those of normal controls [52,53].
Additionally, the neuroimaging method as well as the
neuropsychological tests could help identify the potential
endophenotypic biomarkers that reflect or predict the out-
comes of CBT, which would provide a strong evidence of
the efficacy of psychotherapy [29]. Given the main consid-
eration of core symptoms and the relatively great change
of emotion [12,18,19], these were tested frequently. Fur-
thermore, other aspects were evaluated, as done in previ-
ous studies [12-16,27], at three main endpoints, which
were before treatment, after CBT and after booster ses-
sions, whereas imaging was conducted at the end of
12 weeks because the efficacy of 12 weeks of CBT on
brain functions had not been tested in adult ADHD as
had been done in other studies [54,55].Table 1 Instruments applied at different time points
Instruments Baseline Week 2 to 11 W
ADHD-RS × × ×
CAARS × × ×
SAS × × ×







ADHD-RS, ADHD Rating Scale; CAARS, Conners Adult ADHD Rating Scale Self-report
Scale; BRIEF-A, Behavior Rating Inventory of Executive Function-Adult Version; CANT
impulsiveness scale; SES, self-esteem scale; WHOQOL-BRIEF, World Health OrganizatBlinding and quality control
There is an independent statistician who conducts the
randomization of patients and analyzes the research results.
The participants and endpoint assessors are kept blind dur-
ing the study. Only the principal investigator is informed of
the randomization results at first, and the psychotherapists
are told when the 12 weeks of CBT is completed.
There are two psychiatrists who conduct the CBT and
they have received same systematic psychotherapy train-
ing, including CBT training. They received psychological
training courses held by the Peking University Sixth Hos-
pital and the Chinese Psychological Society. One psych-
iatrist is in charge of the therapy, and the other is the
recorder who writes down all the sessions. There also are
two supervisors, including a psychiatrist and a psychother-
apist. Regular discussion and supervision are conducted
during the study. The assessors are mainly postgraduate
students of psychiatry, and they are trained to use all the
measurement tools and the consistency is rated.
The principal investigator monitors the research pro-
gress and ensures all the steps are taken according the ori-
ginal protocol, and the Ethics Committee supervises the
interests of subjects such as safety and confidentiality.
Power
It is a noninferiority randomized controlled study, and the
primary outcome measure is the mean difference of the
ADHD-RS scores between groups. Since there was no
relevant study that included booster sessions for adult
ADHD, we used the results of a self-controlled prelimin-
ary experimental study. At baseline, the score of the
ADHD rating scale was 29.80 ± 7.67 (n = 15), after CBT
the score was 17.22 ± 7.62 (n = 18), and after booster ses-
sions the score was 10.56 ± 4.98 (n = 16). We assume the
drop-out rate is 10%, because the previous studies showed









Screening Version; SAS, Self-rating Anxiety Scale; SDS, Self-rating Depression
AB, Cambridge Neuropsychological Test Automatic Battery; BIS, Barratt
ion Quality of Life-Brief Version; fMRI, functional magnetic resonance imaging.
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5% and based on the formula (n = 2[(tα + tβ)*σ/δ]^2, n
means number of subjects, tα means t value of alpha, tβ
means t value of beta, σ means population standard devi-
ation, δ means deviation), the sample size is about 73 sub-
jects including 15 patients in the waiting group (group 3),
29 in the CBT group (group 2), and 29 in the CBT with
booster sessions group (group 1). The numbers of subjects
varied in the three groups since the deviations (δ) of
ADHD-RS scores after 12 week CBT and after booster
sessions were different. Considering the real situation with
recruitment, we separated it into three batches, with a
total of 21, 24 and 28 subjects for one time (Table 2).Statistical analysis
The main analysis is a two-group ANCOVA of ADHD
symptoms, emotional symptomatology, executive func-
tion, impulsiveness, self-esteem and life quality at all time
points with baseline scores as covariates. To estimate the
changes with time in every group, the repeated measures
ANOVA will also be used. Furthermore, the neuroimaging
data will be analyzed based on a voxel-by-voxel method
and the general linear model with a one group by two
time points design after pre-processing procedures. The
statistics is based on intent-to-treat (ITT) analysis, and the
last observation carried forward (LOCF) will be used to
address the missing data.
The primary endpoints analysis is ANCOVA with
ADHD-RS scores at 12 and 24 weeks separately as
dependent variables and baseline ADHD-RS scores as
covariates. Other variables that have correlation with
ADHD-RS scores and clinical meanings will also be
considered for covariates such as gender, age, IQ and
education.Discussion
This is the first study to explore the efficacy of booster
sessions of CBT in adult ADHD as far as we know. In
this study, we hypothesize that the 12 weeks of CBT will
affect core symptoms and other functions for patients
compared to waiting group, and that the booster ses-
sions could improve and prolong these effects compared
with patients who receive CBT with no booster sessions.Table 2 Numbers of subjects in three batches of the
study
Batch Group 1 Group 2 Group 3 Total
1 7 7 7 21
2 8 8 8 24
3 14 14 - 28
Total 29 29 15 73
Group 1: Cognitive behavioral therapy (CBT) with booster sessions group;
Group 2: CBT group; Group 3: waiting group.Strengths
This study has several strengths: (1) the randomized con-
trolled design with three arms benefits the efficacy valid-
ation of using both 12 weeks of CBT and booster sessions
in one study, which could be cost and time saving; (2) stan-
dardized diagnostic and assessment instruments including
subjective self-rating scales, and objective computer-based
(CANTAB) and neuroimaging evaluations; (3) the blind
statistician and the same two psychotherapists who have re-
ceived regular training and supervision; (4) the use of the
CBT manual, which has been proven to be effective [12,13];
and (5) the protocol was designed based on the CONSORT
statement, is registered online, and is under the supervision
of an Ethics Committee.Limitations
The exclusion of several comorbidities might narrow the
scope of application of the results since comorbidity is
common for adult ADHD patients and may reflect a more
severe condition. Furthermore, the recruitment of patients
from a single research center could also influence the sam-
ple representatives.
The design of the waiting group could not fully reflect
the effect of intervention by comparison since the placebo
effect could also play a role. So a control group with non-
directive activities, such as group discussion and psychoe-
ducation, might be more comparable. With the limitation
of staff and resources in a single center, this strategy could
be used in multicenter research.
The follow-up time in this study is 48 weeks (1 year),
which could be insufficient for testifying to the prolonged
effect of booster sessions. As the participants are outpa-
tients, we would get the consent of subjects to allow fu-
ture contact and follow-up.
The dropping-out rate might be a little optimistic based
on the data of our group’s previous studies. Since this
study is funded and conducted in consecutive years, the
sample could be more than we estimated.Direction for clinical practice and future study
In this study we aimed to explore the efficacy of CBT
and its booster sessions for adult ADHD. The 12 weeks
of CBT, which has proven effective abroad [12,13],
needs to be validated before applying it to the Chinese
population. Furthermore, we evaluated its effect with
various instruments covering core symptom, emotion,
executive function, self-esteem, life quality, computer-
based neuropsychological tests and neuroimaging scans.
With all these tools, we could identify the aspects that
CBT could influence and those it could not. It might be
conducive for our understanding of the efficacy and
mechanism of psychotherapy, which has remained un-
clear up to now [29].
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value the long-term effect [17] and the real benefit of patients.
Since the effects we published in papers were only transient
results for patients compared with their life, we need to switch
our focus from research success to considering what patients
really need. And the need of booster sessions were found
through the interview with treated patients. The exploration
of efficacy of the booster sessions could give us the answer as
to whether adding a few more sessions could enhance and
prolong the effect of previous therapy. Furthermore, if the re-
sults are positive, the method of attaching booster sessions to
12 weeks CBTcould be beneficial, economical and practical.
In conclusion, future studies could explore CBT with
booster sessions in a more representative sample with com-
mon comorbidities and from several centers and should in-
clude a control group to avoid the placebo effect. Such a
study might further prove the efficacy of CBT for adult
ADHD in China, and evidence of booster session efficacy
would also benefit our clinical practice.
Trial status
Recruitment is ongoing and began in October 2013. The
first patient was randomized in October 2013. As of
June 2014, 66% have been randomized, and the trial is
expected to be completed in July 2016.
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